SNDX — Syndax Pharmaceuticals Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1395937 ·
Last close
$19.90
Market Cap
$1.76B
52W High
$25.59
52W Low
$19.00
ADV30
1,642,658
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 64,864,000 | 62,231,000 | -34,202,000 | -42,673,000 | 472,668,000 | 130,893,000 | 431,046,000 |
| Dec 2025 | 68,728,000 | 66,022,000 | -62,548,000 | -68,014,000 | 529,706,000 | 134,930,000 | 465,076,000 |
| Sep 2025 | 45,871,000 | 43,771,000 | -57,426,000 | -60,715,000 | 551,792,000 | 116,808,000 | 436,362,000 |
| Jun 2025 | 37,958,000 | 36,679,000 | -69,353,000 | -71,847,000 | 596,149,000 | 108,636,000 | 438,725,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-278,163,000
Investing CF
$234,284,000
Financing CF
$20,664,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.79
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,549,253,000
Inventory
$34,948,000
Receivables
$60,693,000
ST Investments
$230,346,000
EBIT TTM
$-205,669,000
Pretax Income TTM
$-243,249,000
Interest Exp TTM
$37,580,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$217,174,000
EBITDA
$-223,768,000
Free Cash Flow
$-186,008,496
Enterprise Value
$1,751,004,928
Total Cash
$361,239,008
Total Debt
$345,360,000
Shares Out
88,610,027
Trailing EPS
$-2.79
Book Value
$0.74
ROE
-189.5%
ROA
-25.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 172,352,000 | -273,084,000 | -285,422,000 | 529,706,000 | 465,076,000 | — | -322,980,000 |
| Dec 2024 | 23,680,000 | -339,672,000 | -318,758,000 | 724,816,000 | 436,692,000 | — | -274,903,000 |
| Dec 2023 | 0 | -229,954,000 | -209,360,000 | 612,880,000 | 58,684,000 | — | -160,601,000 |
| Dec 2022 | 0 | -151,757,000 | -149,338,000 | 497,236,000 | 29,787,000 | — | -133,675,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $1.76B | $16.67 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.74B | $30.09 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.80B | $17.38 | — |
| OCS | Oculis Holding AG | $1.81B | $29.93 | — |
| GLPG | Lakefront Biotherapeutics NV | $1.81B | $27.49 | — |
News headlines (Yahoo Finance, 1h cache)
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness
2026-05-24 08:10 · Yahoo
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
2026-05-21 21:01 · Yahoo
Syndax Announces Participation in Upcoming Investor Conferences
2026-05-20 11:00 · Yahoo
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
2026-05-14 16:50 · Yahoo
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
2026-05-12 14:31 · Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-06 20:01 · Yahoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?
2026-05-01 23:12 · Yahoo
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...
2026-05-01 07:18 · Yahoo
Syndax Pharmaceuticals Q1 Earnings Call Highlights
2026-05-01 02:42 · Yahoo
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
2026-04-30 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.